Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros












Base de datos
Intervalo de año de publicación
1.
Front Psychol ; 15: 1374330, 2024.
Artículo en Inglés | MEDLINE | ID: mdl-38699572

RESUMEN

Metascience scholars have long been concerned with tracking the use of rhetorical language in scientific discourse, oftentimes to analyze the legitimacy and validity of scientific claim-making. Psychology, however, has only recently become the explicit target of such metascientific scholarship, much of which has been in response to the recent crises surrounding replicability of quantitative research findings and questionable research practices. The focus of this paper is on the rhetoric of psychological measurement and validity scholarship, in both the theoretical and methodological and empirical literatures. We examine various discourse practices in published psychological measurement and validity literature, including: (a) clear instances of rhetoric (i.e., persuasion or performance); (b) common or rote expressions and tropes (e.g., perfunctory claims or declarations); (c) metaphors and other "literary" styles; and (d) ambiguous, confusing, or unjustifiable claims. The methodological approach we use is informed by a combination of conceptual analysis and exploratory grounded theory, the latter of which we used to identify relevant themes within the published psychological discourse. Examples of both constructive and useful or misleading and potentially harmful discourse practices will be given. Our objectives are both to contribute to the critical methodological literature on psychological measurement and connect metascience in psychology to broader interdisciplinary examinations of science discourse.

2.
Am J Med Genet A ; 194(4): e63511, 2024 04.
Artículo en Inglés | MEDLINE | ID: mdl-38126162

RESUMEN

Some children exposed at conception to the antiepileptic drugs (AEDs) phenytoin (PHT), phenobarbital (PB), and carbamazepine (CBZ) have changes in their midface and fingers. It has been suggested that the anticonvulsant-exposed child with these subtle changes in facial features (the "anticonvulsant face") has a greater likelihood of having deficits in IQ in comparison with children exposed to the same anticonvulsants who do not have these features. 115 AED-exposed children (40, PHT; 34, PB; and 41, CBZ) between 6.5 and 16 years of age and 111 unexposed children matched by sex, race, and year in school were evaluated. The evaluations were (WISC-III), physical examination with measurements of facial features and digits and photographs. The AED-exposed children had cephalometric radiographs, but not the unexposed. Each parent had a similar examination of face and hands plus tests of intelligence. These AED-exposed children showed an increased frequency of a short nose and anteverted nares, features of the "anticonvulsant face." Lateral skull radiographs showed a decrease in the angle between the anterior cranial base and nasal bone, which produces anteverted nares. Mean IQs were significantly lower on one or more IQ measures for the children with these facial features. Shortening of the distal phalanges and small fingernails correlated with the presence of a short nose in that child. The findings in 115 children exposed at conception to either phenytoin, phenobarbital, or carbamazepine, as monotherapy, confirmed the hypothesis that those with a short nose and anteverted nares had a lower IQ than exposed children without those features.


Asunto(s)
Epilepsia , Anomalías Musculoesqueléticas , Embarazo , Niño , Femenino , Humanos , Anciano de 80 o más Años , Anticonvulsivantes/efectos adversos , Fenitoína/efectos adversos , Epilepsia/tratamiento farmacológico , Fenobarbital/uso terapéutico , Carbamazepina/efectos adversos , Ácido Valproico/uso terapéutico
3.
Epilepsy Behav ; 127: 108533, 2022 02.
Artículo en Inglés | MEDLINE | ID: mdl-35042158

RESUMEN

OBJECTIVE: Usage during pregnancy of the antiseizure medication (ASM), phenobarbital (PB), carbamazepine (CBZ), and phenytoin (PHT), has been associated with adverse pregnancy outcomes. While morphological effects on offspring are well-documented, inconsistent findings have been reported on neuropsychological development, possibly due to differences in attention to maternal demographics, and other design characteristics. Herein, we report the results of a carefully designed protocol used to examine the effects of gestational monotherapy with PB, CBZ, or PHT upon children's general mental abilities, when compared to age- and gender- matched children born to unexposed women of similar age, education, and socioeconomic status. METHODS: For each ASM, we selected qualifying cases from children born to PB, CBZ, or PHT monotherapy-exposed and unexposed women. Following the application of inclusion, exclusion, and matching criteria, our sample included 34 PB-exposed, 40 PHT-exposed, and 41 CBZ-exposed children along with matched unexposed children for each drug group. Criteria were applied through examination of maternal medical and educational histories, parental socioeconomic characteristics, and child's age and gender. Each child's physical and neuropsychological characteristics were examined, using standardized protocols. We report on the cognitive performance of the children as assessed by the Wechsler Intelligence Scale for Children - III (WISC-III), the leading measure of mental ability in the U.S. RESULTS: An overall mixed model ANOVA of the adjusted performance of the children across all groups controlling for maternal IQ revealed significant effects on verbal IQ, but not full-scale IQ or performance IQ. In the individual drug and unexposed group comparisons, only reduced verbal and full-scale IQ scores in PB-exposed versus matched unexposed children were found. Comparisons between drug groups revealed a significant reduction in verbal IQ and full-scale IQ in PB-exposed versus PHT-exposed children, but not in other drug-drug comparisons. SIGNIFICANCE: These results demonstrate effects on children's mental ability due to prenatal PB exposure, such that analyses adjusted for maternal IQ scores, revealed reduced verbal mental abilities and reduced full-scale IQ scores when scores in exposed children were compared to scores from children of the same age and sex born to demographically similar, healthy unexposed women. When comparisons were made between drug groups, children exposed prenatally to PB performed significantly worse than prenatally PHT-exposed children, but CBZ-exposed children's scores were not significantly different from those of PB or PHT-exposed groups. In light of shared effects on structural teratogenicity, these findings suggest that use of PB monotherapy for the management of seizures during pregnancy may be associated with increased risk in comparison to PHT when neurobehavioral functioning is considered, and that only PB-exposed children have reduced performance compared to matched controls. Attention to these effects is critical in the developing world where use of these older medications remains predominant, and prudent choices can be made to reduce impact on cognitive development.


Asunto(s)
Anticonvulsivantes , Fenitoína , Anticonvulsivantes/efectos adversos , Carbamazepina/efectos adversos , Niño , Femenino , Humanos , Pruebas de Inteligencia , Fenobarbital/efectos adversos , Fenitoína/efectos adversos , Embarazo
4.
Neurotoxicol Teratol ; 54: 5-14, 2016.
Artículo en Inglés | MEDLINE | ID: mdl-26791321

RESUMEN

OBJECTIVES: To evaluate adaptive behavior outcomes of children prenatally exposed to lamotrigine, valproate, or carbamazepine, and to determine if these outcomes were dose-dependent. METHODS: Data were collected from women enrolled in the North American Anti epileptic Drug (AED) Pregnancy Registry who had taken lamotrigine, valproate, or carbamazepine monotherapies throughout pregnancy to suppress seizures. The adaptive behavior of 252 exposed children (including 104 lamotrigine-exposed, 97 carbamazepine-exposed, and 51 valproate-exposed), ages 3- to 6-years-old, was measured using the Vineland-II Adaptive Behavior Scales, administered to each mother by telephone. Mean Adaptive Behavior Composite (ABC), domain standard scores for communication, daily living, socialization and motor skills, and adaptive levels were analyzed and correlated with first trimester drug dose. RESULTS: After adjusting for maternal age, education, folate use, cigarette and alcohol exposure, gestational age, and birth weight by propensity score analysis, the mean ABC score for valproate-exposed children was 95.6 (95% CI [91, 101]), versus 100.8 (95% CI [98, 103]) and 103.5 (95% CI [101, 106]) for carbamazepine- and lamotrigine-exposed children, respectively (ANOVA; p=0.017). Significant differences were observed among the three drug groups in the ABC (p=0.017), socialization (p=0.026), and motor (p=0.018) domains, with a trend toward significance in the communication domain (p=0.053). Valproate-exposed children scored lowest and lamotrigine-exposed children scored highest in every category. Valproate-exposed children were most likely to perform at a low or moderately low adaptive level in each category. Higher valproate dose was associated with significantly lower ABC (p=0.020), socialization (p=0.009), and motor (p=0.041) scores before adjusting for confounders. After adjusting for the above variables, increasing VPA dose was associated with decreasing Vineland scores in all domains, but the relationships were not statistically significant. No dose effect was observed for carbamazepine or lamotrigine. CONCLUSIONS: Unlike carbamazepine and lamotrigine, prenatal valproate exposure was associated with adaptive behavior impairments with specific deficits in socialization and motor function, along with a relative weakness in communication. Increasing valproate dose was associated with a decline in adaptive functioning. This finding of a linear dose-dependent teratogenic effect suggests that valproate should be avoided at any dose during pregnancy. However, some women with epilepsy controlled only by valproate will decide, in consultation with their provider, that the benefits of continuing valproate during pregnancy outweigh the fetal risks. Faced with difficult choices, clinicians should be supportive as these patients consider their options.


Asunto(s)
Anticonvulsivantes/efectos adversos , Discapacidades del Desarrollo/etiología , Síndrome de Adaptación General/etiología , Complicaciones del Embarazo/inducido químicamente , Efectos Tardíos de la Exposición Prenatal/fisiopatología , Efectos Tardíos de la Exposición Prenatal/psicología , Análisis de Varianza , Carbamazepina , Niño , Preescolar , Epilepsia/tratamiento farmacológico , Femenino , Humanos , Lamotrigina , Masculino , Embarazo , Efectos Tardíos de la Exposición Prenatal/inducido químicamente , Triazinas , Ácido Valproico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...